DermTech Products Added To Department Of Veterans Affairs National Acquisition Ceter Catalog
https://www.vendorportal.ecms.va.gov/NAC/Search/Details/36F79723D0013
Collaboration With Kiora Pharmaceuticals And The Royal Adelaide Hospital, Leading Australian CRO, Accelagen Clinical Trial Underway To Improve Vision In Individuals With Advanced Retinitis Pigmentosa
Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301.
MELBOURNE, Australia, Feb. 14, 2023 /PRNewswire/ -- In collaboration with US-based
Humanigen Has Received A Notice Of Allowance For Its U.S. Patent Application 16/652,977 Titled “Methods Of Treating Immunotherapy-Related Toxicity Using A GM-CSF Antagonist”.
https://patentcenter.uspto.gov/#!/applications/16652977/ifw/docs
Verve Therapeutics Announced VERVE-101 Awarded Innovation Passport By UK MHRA For Treatment Of Heterozygous Familial Hypercholesterolemia
Verve Therapeutics, Inc. today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).
Cullinan Oncology Licenses U.S. Rights To The First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator From Harbour BioMed; Currently In A Phase 1 Clinical Study Being Conducted At U.s. And Australian Sites In Patients With Advanced Solid Tumors
Cullinan Oncology, Inc. (NASDAQ:CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and
Opdivo In Combination With CABOMETYX Shows Durable Survival With Over Three Years Of Follow-Up In The CheckMate -9ER Trial In First-Line Advanced Renal Cell Carcinoma
Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to
MacroGenics Highlights Preliminary Clinical Results From Single Arm Study Of Lorigerlimab
Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved
Aravive To Present Updated Data From Phase 1b Trial Of Batiraxcept
ravive, Inc. (NASDAQ:ARAV, ", the Company", )))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its